November 30, 2020

Antibe Therapeutics Announces TSX Approval and Effective Date of Share Consolidation

TORONTO, CANADA — (November 30, 2020) – Antibe Therapeutics Inc (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that, further to a press release issued on November 17, 2020, the consolidation (“Consolidation”) of the Company’s issued and outstanding common … Continued

read
November 24, 2020

Antibe Therapeutics Strengthens Governance and U.S. Capital Markets Expertise With Appointment of Two Independent Directors

TORONTO, CANADA — (November 24, 2020) – Antibe Therapeutics Inc (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the appointment of Robert E. Hoffman and Jennifer McNealey to its Board of Directors. “We are delighted to welcome Jennifer and … Continued

read
November 17, 2020

Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing

TORONTO, CANADA — (November 17, 2020) – Antibe Therapeutics Inc (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that it intends to complete a consolidation of its issued and outstanding common shares (“Common Shares”) on the basis of one … Continued

read
November 13, 2020

Antibe Therapeutics Reports Q2 2021 Interim Financial and Operating Results

TORONTO, CANADA — (November 13, 2020) – Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the filing of its financial and operating results for the fiscal quarter ended September 30, 2020. The Company’s unaudited fiscal Q2 … Continued

read
October 30, 2020

Antibe Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock Exchange

TORONTO, CANADA — (October 30, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (“TSX”) to graduate from the TSX Venture Exchange … Continued

read
September 15, 2020

Antibe Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit

TORONTO, CANADA — (September 15, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that Dan Legault, Antibe’s Chief Executive Officer, will present a corporate overview at the upcoming virtual Oppenheimer Fall Healthcare Life Sciences … Continued

read
August 31, 2020

Antibe Therapeutics to Present at Upcoming Conferences

TORONTO, CANADA — (August 31, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announced that the Company will be presenting at two conferences: LD Micro 500 – Virtual Event September 1, 2020 – 12:20pm (Eastern Time) ld500.ldmicro.com Antibe has also been invited to participate in the TSX Venture 50™ Capital Conference for the … Continued

read
August 25, 2020

Antibe Therapeutics Reports Q1 2021 Interim Financial and Operating Results

TORONTO, CANADA — (August 24, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Monday, August 24 for the fiscal quarter ended June 30, 2020. The Company’s unaudited fiscal Q1 2021 condensed interim consolidated financial statements and MD&A are available on SEDAR. About Antibe Therapeutics Inc. Antibe develops safer, … Continued

read
August 21, 2020

Antibe Therapeutics Announces Results of Annual and Special Meeting

TORONTO, CANADA — (August 20, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual and special meeting held earlier today. All resolutions outlined in the management information circular (the “Circular”) were approved, including: The election of directors (Roderick Flower, Amal Khouri, Daniel Legault, Walt Macnee, John … Continued

read
August 6, 2020

Antibe Therapeutics Engages Stern IR for Investor Relations Services

TORONTO, CANADA — (August 6, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announces that it has engaged Stern Investor Relations, Inc. (“Stern IR”) to expand the Company’s investor relations program and support efforts to broaden visibility within the US capital markets. “We are excited to have engaged Stern IR as our new investor … Continued

read
August 4, 2020

Antibe Therapeutics Provides Corporate Update

 – Phase II secondary data confirmed remarkable potency of ATB-346 – – 3rd party commercial studies project peak annual sales of $5.3 billion across seven key countries – – Large market partnering efforts to accelerate in parallel with Phase III program – – Non-opioid painkiller advancing towards the clinic; pipeline expansion initiatives underway – TORONTO, … Continued

read
July 24, 2020

Antibe Therapeutics Reports 2020 Year-End Financial and Operating Results

TORONTO, CANADA — (July 24, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020. The Company’s audited 2020 consolidated financial statements, MD&A and AIF are available on SEDAR. About Antibe Therapeutics Inc. Antibe develops safer, … Continued

read
June 30, 2020

Antibe Therapeutics Announces Closing of $28.75 Million Bought Deal Offering

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (June 30, 2020) — Antibe Therapeutics Inc. (TSXV: ATE) announced that it closed its previously announced bought deal public offering of 62,500,000 units of the Company (the “Units“) at a price of $0.40 per Unit (the “Offering Price“) plus … Continued

read
June 9, 2020

Antibe Therapeutics Announces $25 Million Bought Deal Unit Offering

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (June 9, 2020) — Antibe Therapeutics Inc. (TSXV: ATE) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by Bloom Burton Securities Inc. and including Echelon Wealth Partners Inc., Paradigm Capital … Continued

read
June 1, 2020

Antibe Therapeutics Announces Positive Top-Line Data from Phase 2B Dose-Ranging, Efficacy Study for ATB-346

– ATB-346 demonstrates superiority to placebo in reducing osteoarthritis pain – – ATB-346 is more potent than expected; lowest effective dose still to be established – – Antibe plans pivotal Phase 2/3 adaptive registration trial – TORONTO, CANADA — (June 1, 2020) — Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that … Continued

read
May 6, 2020

Antibe Therapeutics Announces the Hiring of Chief Medical Officer

– Dr. Joseph Stauffer, an anesthesiologist with deep clinical and regulatory experience, fills a key position as Antibe prepares for late-stage development and partnering – TORONTO, CANADA — (May 6, 2020) — Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the hiring of Dr. Joseph Stauffer in the new role of Chief … Continued

read
February 28, 2020

Antibe Therapeutics Announces Enrollment of Last Patient in Phase 2B Dose-Ranging, Efficacy Study of Lead Drug, ATB-346

TORONTO, CANADA — (February 28, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that the last patient has been enrolled and is on treatment in the Phase 2B dose-ranging, efficacy study of Antibe’s lead drug, … Continued

read
February 25, 2020

Antibe Therapeutics Provides Corporate Update and Reports Q3 2020 Interim Financial and Operating Results

TORONTO, CANADA — (February 25, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update in conjunction with the filing of its financial and operating results for the fiscal quarter ended December 31, 2019. … Continued

read
February 24, 2020

Antibe Therapeutics Announces Research Publication Demonstrating Markedly Enhanced Pain Relief and Increased Safety of Second Pipeline Drug

TORONTO, CANADA — (February 24, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the publication of a multi-national study entitled “Enhanced Analgesic Effects and GI Safety of A Novel Hydrogen Sulfide-Releasing Anti- Inflammatory Drug (ATB-352): … Continued

read

archives

Attention

This is an external link. Click “OK” to continue.

CANCEL OK